IRCT20201202049568N2 IRCT 2021-02-22 Tehran University of Medical Sciences Safety and efficacy of Mesenchymal Stem Cell administration in Bronchiolitis Obliterans Syndrome. Evaluation of safety and efficacy of allogeneic adipose-derived mesenchymal stem cell administration in Bronchiolitis Obliterans Syndrome (BOS) after allogeneic hematopoietic stem cell transplantation. 2020-12-21 anticipated 10 Complete https://irct.ir/trial/53143 interventional Randomization: Not randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Single, Purpose: Treatment, Other design features: Pilot study. N/A bronchiolitis obliterans. Intervention group: mesenchymal stem cells from the donors' adipose tissue will be extracted and then cultured in the laboratory. Final products will be injected with a dosage of 1 million per kg intravenously to the patients. All the patients will be hospitalized for 24 hours for further observation.. Yes - There is a plan to make this available What will be shared: The data regarding the primary and secondary outcomes without any identifiable personal data will be shared. When: Six months after the publication of the results of this study To whom: Investigators in academic institutions. Conditions: Medical doctors or scientists who are conducting studies in the same subject including mesenchymal stem cell therapy or bronchiolitis obliterans. Where to obtain: The data that support the findings of this study will be available on request from the corresponding author. The data will not be publicly available due to privacy and ethical considerations. How to obtain: The data that support the findings of this study will be available on request from the corresponding author. The data will not be publicly available due to privacy and ethical considerations. Comments: